ProCE Banner Activity

FAQs: Multidisciplinary Care During BTK Inhibitor or Venetoclax-Based Therapy for Patients With CLL

Clinical Thought

In this brief commentary, 2 expert pharmacists answer frequently asked questions on the use of BTK inhibitors and venetoclax-based therapy for patients with CLL.

Released: March 20, 2023

Expiration: March 18, 2024

Share

Faculty

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships to disclose.

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.